{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T04:28:28Z","timestamp":1793593708282,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.xphs.2026.104555","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T06:17:08Z","timestamp":1792563428000},"page":"104555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impurities of impurities! Investigation of drug-related nitrosated impurities of omeprazole using optimized forced nitrosation conditions"],"prefix":"10.1016","volume":"116","author":[{"given":"Shivashankar","family":"Pathinti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munesh","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol G.","family":"Dikundwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.xphs.2026.104555_bib0001","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1021\/acs.oprd.3c00153","article-title":"Formation of N-nitrosamine drug substance related impurities in medicines: a regulatory perspective on risk factors and mitigation strategies","volume":"27","author":"Cioc","year":"2023","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.xphs.2026.104555_bib0002","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.chemosphere.2018.07.098","article-title":"Critical review of major sources of human exposure to N-nitrosamines","volume":"210","author":"Gushgari","year":"2018","journal-title":"Chemosphere"},{"issue":"2","key":"10.1016\/j.xphs.2026.104555_bib0003","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jsps.2022.12.010","article-title":"An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals","volume":"31","author":"Wichitnithad","year":"2023","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.xphs.2026.104555_bib0004","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jpba.2018.11.010","article-title":"NDMA impurity in valsartan and other pharmaceutical products: analytical methods for the determination of N-nitrosamines","volume":"164","author":"Parr","year":"2019","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"10.1016\/j.xphs.2026.104555_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18253","article-title":"In vitro analysis of N-nitrosodimethylamine (NDMA) formation from ranitidine under simulated gastrointestinal conditions","volume":"4","author":"Gao","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.xphs.2026.104555_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115066","article-title":"N-Nitrosodimethylamine formation in metformin hydrochloride sustained-release tablets: effects of metformin and hypromellose used in drug product formulation","volume":"222","author":"Hao","year":"2023","journal-title":"J Pharm Biomed Anal"},{"issue":"5","key":"10.1016\/j.xphs.2026.104555_bib0007","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.xphs.2022.11.011","article-title":"Ranitidine: a proposed mechanistic rationale for NDMA formation and a potential control strategy","volume":"112","author":"Harmon","year":"2023","journal-title":"J Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2026.104555_bib0008","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1080\/14740338.2021.1917547","article-title":"Investigating the root cause of N-nitrosodimethylamine formation in metformin pharmaceutical products","volume":"20","author":"Nasr","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.xphs.2026.104555_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113460","article-title":"Determination of N-nitrosodimethylamine and N-nitrosomethylethylamine in drug substances and products of sartans, metformin and ranitidine by precipitation and solid phase extraction and gas chromatography\u2013tandem mass spectrometry","volume":"189","author":"Lim","year":"2020","journal-title":"J Pharm Biomed Anal"},{"issue":"4","key":"10.1016\/j.xphs.2026.104555_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202100435","article-title":"Risk assessment for nitrosated pharmaceuticals: a future perspective in drug development","volume":"355","author":"Schmidtsdorff","year":"2022","journal-title":"Arch Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2026.104555_bib0011","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202200484","article-title":"Prevalence of nitrosamine contaminants in drug samples: has the crisis been overcome?","volume":"356","author":"Schmidtsdorff","year":"2023","journal-title":"Arch Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2026.104555_bib0012","article-title":"Appendix 1: acceptable intakes established for N-nitrosamines reference number: EMA\/72902\/2024","volume":"4","year":"2024","journal-title":"Rev"},{"key":"10.1016\/j.xphs.2026.104555_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.01.016","article-title":"Risk assessment and management strategy of two new nitrosamine drug substance related impurities (NDSRIs) in a pharmaceutical drug product for the treatment of a rare disease-from prediction to control","author":"Mukherjee","year":"2025","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2026.104555_bib0017","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1021\/acs.oprd.3c00084","article-title":"Approaches and considerations for the investigation and synthesis of N-nitrosamine drug substance-related impurities (NDSRIs)","volume":"27","author":"Ashworth","year":"2023","journal-title":"Org Process Res Dev"},{"issue":"6","key":"10.1016\/j.xphs.2026.104555_bib0018","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1021\/acs.chemrestox.3c00083","article-title":"Computational prediction of metabolic \u03b1-carbon hydroxylation potential of N-nitrosamines: overcoming data limitations for carcinogenicity assessment","volume":"36","author":"Chakravarti","year":"2023","journal-title":"Chem Res Toxicol"},{"issue":"5","key":"10.1016\/j.xphs.2026.104555_bib0019","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.xphs.2022.12.022","article-title":"Regulatory experiences with root causes and risk factors for nitrosamine impurities in pharmaceuticals","volume":"112","author":"Horne","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104555_bib0020","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/dta.3874","article-title":"Quantitative investigation of nitrosamine drug substance-related impurities (NDSRIs) under artificial gastric conditions by liquid chromatography\u2013tandem mass spectrometry and structure\u2013activity relationship analysis","volume":"17","author":"Vogel","year":"2025","journal-title":"Drug Test Anal"},{"issue":"10","key":"10.1016\/j.xphs.2026.104555_bib0021","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1021\/acs.oprd.3c00153","article-title":"Formation of N-nitrosamine drug substance related impurities in medicines: a regulatory perspective on risk factors and mitigation strategies","volume":"27","author":"Cioc","year":"2023","journal-title":"Org Process Res Dev"},{"issue":"9","key":"10.1016\/j.xphs.2026.104555_bib0022","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1021\/acs.oprd.0c00224","article-title":"Potential for the formation of N-nitrosamines during the manufacture of active pharmaceutical ingredients: an assessment of the risk posed by trace nitrite in water","volume":"24","author":"Ashworth","year":"2020","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.xphs.2026.104555_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.scp.2025.102032","article-title":"Determination of potential genotoxic NDSRIs (nitrosamine drug substance related impurities) in quetiapine fumarate\u2013antipsychotic medication:(Q) SAR assessment, UPLC-ESI-MS\/MS method development, validation and its analytical greenness evaluation","volume":"45","author":"Pepakayala","year":"2025","journal-title":"Sustain Chem Pharmacy"},{"key":"10.1016\/j.xphs.2026.104555_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2025.114065","article-title":"Strategic approaches to elevate quality and sustainability of NDSRIs method development: synthesis and a simultaneous quantification study of multiple tamsulosin NDSRIs","author":"Nakka","year":"2025","journal-title":"Microchem J"},{"issue":"5","key":"10.1016\/j.xphs.2026.104555_bib0026","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.xphs.2023.02.024","article-title":"Modified NAP test: a simple and responsive nitrosating methodology for risk evaluation of NDSRIs","volume":"112","author":"Sharma","year":"2023","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2026.104555_bib0027","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12247-025-10112-6","article-title":"Forced nitrosation as a tool for proactive N-nitrosamine drug substance related impurities risk assessment in sartans co-formulated with hydrochlorothiazide","volume":"20","author":"Patel","year":"2025","journal-title":"J Pharm Innovat"},{"issue":"19","key":"10.1016\/j.xphs.2026.104555_bib0028","doi-asserted-by":"crossref","first-page":"7294","DOI":"10.1039\/C9NJ00932A","article-title":"Identification and structural characterization of the stress degradation products of omeprazole using Q-TOF-LC-ESI-MS\/MS and NMR experiments: evaluation of the toxicity of the degradation products","volume":"43","author":"Shankar","year":"2019","journal-title":"New J Chem"},{"key":"10.1016\/j.xphs.2026.104555_bib0029","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jpba.2015.10.005","article-title":"Development of RP UPLC-TOF\/MS, stability indicating method for omeprazole and its related substances by applying two level factorial design; and identification and synthesis of non-pharmacopoeial impurities","volume":"118","author":"Jadhav","year":"2016","journal-title":"J Pharm Biomed Anal"},{"issue":"10","key":"10.1016\/j.xphs.2026.104555_bib0030","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1021\/jo01021a027","article-title":"Aromatic substitution. XXIII. 1 nitration and nitrosation of pyridine with nitronium and nitrosonium tetrafluoroborate. isolation of N-nitro-and N-nitrosopyridinium tetrafluoroborates","volume":"30","author":"Olah","year":"1965","journal-title":"J Org Chem"},{"issue":"1","key":"10.1016\/j.xphs.2026.104555_bib0031","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0003-2670(03)00076-X","article-title":"Acid\u2013base chemistry of omeprazole in aqueous solutions","volume":"481","author":"Yang","year":"2003","journal-title":"Anal Chim Acta"},{"issue":"5","key":"10.1016\/j.xphs.2026.104555_bib0032","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.xphs.2022.11.013","article-title":"The landscape of potential small and drug substance related nitrosamines in pharmaceuticals","volume":"112","author":"Schlingemann","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104555_bib0033","first-page":"1","article-title":"A comprehensive degradation study and identification of key degradation products of omeprazole drug substance including its degradation pathways using LC-HRMS and NMR","author":"Rathnasekara","year":"2025","journal-title":"J Liq Chromatogr Relat Technol"},{"issue":"6","key":"10.1016\/j.xphs.2026.104555_bib0034","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/jaoac\/93.6.1811","article-title":"Ultra-fast gradient LC method for omeprazole analysis using a monolithic column: assay development, validation, and application to the quality control of omeprazole enteric-coated pellets","volume":"93","author":"Borges","year":"2010","journal-title":"J AOAC Int"},{"issue":"5","key":"10.1016\/j.xphs.2026.104555_bib0035","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/chromsci\/bmw008","article-title":"Development and validation of a novel stability-indicating RP-HPLC method for the simultaneous determination of related substances of ketoprofen and omeprazole in combined capsule dosage form","volume":"54","author":"Koppala","year":"2016","journal-title":"J Chromatogr Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104555_bib0036","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3797\/scipharm.1209-12","article-title":"A single gradient stability-indicating reversed-phase LC method for the estimation of impurities in omeprazole and domperidone capsules","volume":"81","author":"Seshadri","year":"2012","journal-title":"Sci Pharm"},{"key":"10.1016\/j.xphs.2026.104555_bib0038","series-title":"Modified Release Benzimidazole Formulations (WO 2012\/092486 A3)","author":"Lingam","year":"2012"},{"key":"10.1016\/j.xphs.2026.104555_bib0039","series-title":"Pharmaceutical Composition of Omeprazole (EP 2 773 348 B1)","author":"Jaume","year":"2018"},{"key":"10.1016\/j.xphs.2026.104555_bib0040","series-title":"Omeprazole Formulations (US 2020\/0179288 A1)","author":"Staric","year":"2020"},{"issue":"9","key":"10.1016\/j.xphs.2026.104555_bib0041","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1021\/acs.oprd.0c00323","article-title":"Pathways for N-nitroso compound formation: secondary amines and beyond","volume":"24","author":"L\u00f3pez-Rodr\u00edguez","year":"2020","journal-title":"Org Process Res Dev"},{"issue":"59","key":"10.1016\/j.xphs.2026.104555_bib0042","first-page":"233","article-title":"Monitoring endogenous nitrosamine formation in man","author":"Ohshima","year":"1984","journal-title":"IARC Sci Publ"},{"key":"10.1016\/j.xphs.2026.104555_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.113933","article-title":"Identification and structural characterization of potential degraded impurities of ribociclib by time of flight-tandem mass spectrometry, and their toxicity prediction","volume":"197","author":"Sahu","year":"2021","journal-title":"J Pharm Biomed Anal"},{"issue":"10","key":"10.1016\/j.xphs.2026.104555_bib0044","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/jms.4266","article-title":"Identification and characterization of stress degradation products of sumatriptan succinate by using LC\/Q-TOF-ESI-MS\/MS and NMR: toxicity evaluation of degradation products","volume":"53","author":"Udutha","year":"2018","journal-title":"J Mass Spectrom"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926004028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926004028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T04:25:49Z","timestamp":1793593549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926004028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["S0022354926004028"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104555","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impurities of impurities! Investigation of drug-related nitrosated impurities of omeprazole using optimized forced nitrosation conditions","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104555","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104555"}}